24 AFIAS test cassettes for the quantitative determination of D-dimer in human whole blood or plasma.
Package contents:
24 AFIAS test cassettes
24 pipette tips
1 ID chip
1 package insert
Exclusively for professional users
Discover more than 2,000 medical and toxicological tests and POCT solutions
Please note: The prices shown are basic list prices. Your individual prices will be displayed after you have logged in to the shop. Your personal customer advisors can add them at any time.
The AFIAS D-Dimer Test is a fluorescence immunoassay (FIA) for the quantitative determination of D-Dimer in human whole blood/plasma. The test is used as an aid in the management and monitoring of therapeutic evaluation of patients with thromboembolic disease. For in vitro diagnostic use only.
D-dimer, a breakdown product of cross-linked fibrin formed during activation of the coagulation system, is commonly used to rule out thromboembolism in outpatients with suspected deep vein thrombosis (DVT) and pulmonary embolism (PE). DVT and PE are relatively common and can cause sudden, fatal embolic events in the pulmonary arteries and other regions. Measurement of plasma D-dimer levels has been used as a screening strategy for subclinical DVT. A systematic review found that a normal range of high-sensitivity D-dimer level excludes DVT in patients with a low or intermediate clinical probability of DVT. DVT is a risk factor for stroke due to advanced age, hemiplegia and coagulation disorders, and DVT can lead to paradoxical embolic stroke via a right-to-left shunt. Therefore, it is important to monitor the occurrence of DVT in acute stroke patients by the level of D-dimer. Plasma D-dimer levels have been shown to be useful in screening for DVT in patients with chronic stroke National and international scientific organisations have suggested the use of these markers in implementing new diagnostic strategies in patients with coronary syndromes. As D-dimer is known to be an important prognostic indicator for heart disease, its most important role is to monitor the clinical condition after treatment and to evaluate patients post-therapeutically.
